Retatrutide

Retatrutide represents a new generation of metabolic peptides beyond the GLP-1 and dual GIP/GLP-1 class. By adding glucagon receptor agonism to the GIP and GLP-1 targets, retatrutide unlocks a third metabolic pathway: increased energy expenditure and hepatic fat oxidation. This tripartite mechanism produces additive and potentially synergistic weight loss exceeding that of tirzepatide (dual GIP/GLP-1) or semaglutide (GLP-1 alone).

The peptide is modified with a C18 fatty acid chain conjugated to a lysine residue, enabling reversible albumin binding that extends its half-life to approximately 6 days — supporting once-weekly subcutaneous dosing. It was engineered to maintain high potency at all three receptors with balanced agonist activity, unlike earlier glucagon agonists that caused unacceptable hyperglycemia when used alone.

Phase 2 results published in NEJM (2023) showed participants receiving 12 mg/week lost an average of 24.2% of body weight over 48 weeks, with additional improvements in HbA1c, triglycerides, liver fat, and blood pressure. Phase 3 trials (TRIUMPH program) are ongoing.

// TRIPLE RECEPTOR AGONISM

Retatrutide simultaneously activates three receptors: (1) GIP-R — reduces appetite, improves glucose disposal, and promotes fat metabolism in adipose tissue; (2) GLP-1R — stimulates glucose-dependent insulin secretion, slows gastric emptying, and reduces food intake via hypothalamic satiety signaling; (3) GCGR (glucagon receptor) — increases hepatic glucose output (managed by the GLP-1 component), promotes lipolysis, and critically drives thermogenesis and energy expenditure. The balanced co-activation prevents the hyperglycemia that would occur with glucagon agonism alone.

// EXTENDED HALF-LIFE VIA ALBUMIN BINDING

A C18 fatty acid is conjugated to a lysine residue in the peptide chain, enabling reversible non-covalent binding to serum albumin. This extends the effective half-life to ~6 days, allowing once-weekly dosing while maintaining stable receptor engagement. This is the same engineering approach used in semaglutide (Ozempic).

// HEPATIC FAT REDUCTION

The glucagon receptor component activates hepatic PPAR-α and promotes mitochondrial fatty acid beta-oxidation. Phase 2 data showed significant reductions in liver fat content (MRI-measured), positioning retatrutide as a potential treatment for MASLD (metabolic-associated steatotic liver disease) beyond obesity.

Phase 2 results (NEJM, 2023): 338 adults with BMI ≥27 received escalating doses up to 12 mg/week for 48 weeks. The 12 mg dose cohort achieved 24.2% weight loss vs. 2.1% placebo — a treatment difference of approximately 22%. Notably, ~83% of participants achieved ≥5% weight loss and 26% achieved ≥25% weight loss.

Phase 3 TRIUMPH program: Includes trials in obesity, obesity with T2D, and cardiovascular outcomes. Results expected 2025–2026.

Side effects mirror GLP-1 class: nausea (most common), vomiting, diarrhea, constipation. Dose-escalation protocol over 12+ weeks is used to minimize GI tolerability issues. No signals of pancreatitis or thyroid tumors reported in Phase 2 beyond class expectations.